Operating Margin - Virbac SA (PAR:VIRP)

Watchlist Manager

Watchlist

Price: 350.5 EUR 0.29%

Market Cap: 2.9B EUR

31.1%

Current

20%

Average

Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin

31.1%

Operating Profit

551.5m

Revenue

1.8B

Operating Margin Across Competitors

Country		Company	Market Cap	Operating Margin
FR		Virbac SA PAR:VIRP	2.9B EUR	31%
US		Eli Lilly and Co NYSE:LLY	1T USD	44%
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	3%
US		Johnson & Johnson NYSE:JNJ	498.9B USD	27%
CH		Roche Holding AG SIX:ROG	258.9B CHF	34%
UK		AstraZeneca PLC LSE:AZN	211.4B GBP	24%
CH		Novartis AG SIX:NOVN	208.6B CHF	33%
US		Merck & Co Inc NYSE:MRK	260.5B USD	38%
DK		Novo Nordisk A/S CSE:NOVO B	1.3T DKK	42%
IE	E	Endo International PLC LSE:0Y5F	209B USD	11%
US		Pfizer Inc NYSE:PFE	143.3B USD	29%

Virbac SA
Glance View

Economic Moat

None

Market Cap

2.9B EUR

Industry

Pharmaceuticals

Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

View VIRP Analysis

VIRP Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication
US	Chevron Corp NYSE:CVX	Energy

	Johnson & Johnson NYSE:JNJ	207.32 USD 0.46%
	Berkshire Hathaway Inc NYSE:BRK.A	750 005.66 USD 0.59%
	Bank of America Corp NYSE:BAC	55.88 USD 1.1%
	Mastercard Inc NYSE:MA	575.7 USD 0.61%
	UnitedHealth Group Inc NYSE:UNH	325.16 USD -0.69%
	Exxon Mobil Corp NYSE:XOM	118.15 USD 1.25%

	Franklin Covey Co NYSE:FC	17 USD 0.71%
	Mohawk Industries Inc NYSE:MHK	108.58 USD 0.65%
	Ardmore Shipping Corp NYSE:ASC	10.79 USD -0.92%
	ASGN Inc NYSE:ASGN	49.06 USD 0.53%
	Skyworks Solutions Inc NASDAQ:SWKS	65.24 USD 0.87%
	Weatherford International PLC NASDAQ:WFRD	80.47 USD 2.08%

	Johnson & Johnson NYSE:JNJ	207.32 USD 0.46%
	Bank of America Corp NYSE:BAC	55.88 USD 1.1%
	Mastercard Inc NYSE:MA	575.7 USD 0.61%
	Salesforce Inc NYSE:CRM	264.63 USD 1.82%
	Abbvie Inc NYSE:ABBV	227.91 USD 0.48%
	Home Depot Inc NYSE:HD	346.39 USD 0.4%

	Monolithic Power Systems Inc NASDAQ:MPWR	945.16 USD 0.86%
	Applovin Corp NASDAQ:APP	733.6 USD 1.7%
	NVIDIA Corp NASDAQ:NVDA	183.69 USD 1.49%
	Cal-Maine Foods Inc NASDAQ:CALM	83.35 USD -2.74%
	Pro Medicus Ltd ASX:PME	230.34 AUD 3.62%
	Lundin Gold Inc TSX:LUG	120.46 CAD 5.95%

Virbac SA
PAR:VIRP